Projected Earnings Date: 2023-10-30    (Delayed quote data   )
Last
 
Change
 ⇓ 0.00   (%)
Volume
  0
Open
 
High
 
Low
 
8EMA (Daily)
 0.00
40EMA (Daily)
 
50EMA (Daily)
 
STO (Daily)
 
MACD Hist (Daily)
 
8EMA (Weekly)
 0.995
40EMA (Weekly)
 5.61
50EMA (Weekly)
 9.03
STO (Weekly)
 3.828
MACD Hist (Weekly)
 0.483
Athenex Inc is a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer. Its current clinical pipeline is derived from Orascovery, based on a P-glycoprotein (P-gp) pump inhibitor, Src Kinase inhibition, T-cell receptor-engineered T-cells, and arginine deprivation therapy technology platforms. It is primarily engaged in conducting research and development activities through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting preclinical and clinical testing, recruiting personnel, identifying and evaluating additional drug candidates for potential in-licensing or acquisition, and raising capital to support development and commercialization activities.
optionchance optionchance
Home | Chart and Research | Education | About Us  

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.

Questions or Comments: support@optionchance.com
Copyright © 2025 OptionChance.com